Edition:
United States

Pharmaceuticals

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL...

4:30pm EST

Peregrine Pharma reports Q2 shr loss $0.31

Dec 11 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2018 AND RECENT DEVELOPMENTS.Q2 LOSS PER SHARE $0.31.- COMPANY MAINTAINS ITS MANUFACTURING REVENUE GUIDANCE FOR FULL FY 2018 OF $50 MILLION - $55 MILLION.-...

4:05pm EST

Kyprolis (Carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma

Dec 11 (Reuters) - Amgen Inc ::KYPROLIS® (CARFILZOMIB) EXTENDED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN PHASE 3 ASPIRE TRIAL.AMGEN INC - STUDY MET KEY SECONDARY ENDPOINT OF OS.AMGEN INC - SAFETY DATA FROM ASPIRE WAS CONSISTENT WITH KNOWN SAFETY PROFILE OF...

4:00pm EST

Mylan Says Teva Has Dismissed Its Pending Litigation Against Co

Dec 11 (Reuters) - Mylan Nv ::MYLAN NV - ANNOUNCED THAT TEVA HAS DISMISSED ITS PENDING DISTRICT COURT LITIGATION AGAINST MYLAN.MYLAN NV - TEVA HAS AGREED TO WITHDRAW IRISH EQUIVALENT TO THE PATENTS FROM RECENTLY FILED PROCEEDING IN IRELAND.MYLAN NV - TEVA'S PENDING LITIGATION AGAINST CO IS REGARDING...

12:16pm EST

Restructuring & Reorganization

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.